Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics Inc (NQ: PTGX )

46.76 +0.92 (+2.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers 
Via Benzinga
Protagonist Therapeutics Dives As Its Drama Continues With A New FDA Concern
The FDA could revoke a key designation for one of Protagonist's leading drugs. 
Via Investor's Business Daily
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
The biggest pre-market stock movers for Thursday are ready and waiting so let's see what's moving the market this morning! 
Via InvestorPlace
Protagonist Therapeutics Earns $25M Milestone Payment From Janssen Biotech
Via Benzinga
Analyst Ratings For Protagonist Therapeutics
Analysts have provided the following ratings for Protagonist Therapeutics (NASDAQ: 
Via Benzinga
FDA Intends To Revoke Protagonist Therapeutics' Rusfertide Breakthrough Tag In Rare Form Of Blood Cancer
Protagonist Therapeutics Inc (NASDAQ: PTGX) 
Via Benzinga
Protagonist Therapeutics's Return On Capital Employed Overview
Benzinga Pro data, Protagonist Therapeutics (NASDAQ:PTGX) reported Q4 sales of $8.62 million. Earnings fell to a loss of $36.91 million, resulting in a 9.18% decrease from last... 
Via Benzinga
3 Desirable Drug Stocks With Very Promising Pipelines
Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider. 
Via InvestorPlace
Protagonist To Go Ahead With Oral Peptide PN-235, Discontinues Phase 1 Candidate
Protagonist Therapeutics Inc (NASDAQ: PTGX) has selected PN-235 (JNJ-77242113) as the final candidate for all clinical studies in multiple indications based on the... 
Via Benzinga
The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Protagonist to Discontinue Development Of Early-Stage Inflammatory Diseases... 
Via Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
What 9 Analyst Ratings Have To Say About Protagonist Therapeutics
Over the past 3 months, 9 analysts have published their opinion on Protagonist Therapeutics (NASDAQ: 
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Why Protagonist Therapeutics Stock Skyrocketed 80.2% Last Month
Following huge swings over the last two months, the biotech stock is now up 67% year to date. 
Via The Motley Fool
Exposures Product Safety
5 Short Squeeze Candidates To Watch: Progenity Tops List Again, Augmented Reality Play WiMi Hologram Joins List
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: GME) or AMC Entertainment Holdings Inc (NYSE: AMC). A... 
Via Benzinga
5 Short Squeeze Candidates To Watch: Progenity, Digital Brands Top List Again, SPAC AGC Joins Ahead Of Merger
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next GameStop Corp (NYSE: GME) or AMC Entertainment Holdings Inc (NYSE: AMC). A... 
Via Benzinga
The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas... 
Via Benzinga
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news.... 
Via Benzinga
Exposures Product Safety
What 10 Analyst Ratings Have To Say About Protagonist Therapeutics
Analysts have provided the following ratings for Protagonist Therapeutics (NASDAQ: 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
MKM Partners raised the price target on Continental Resources, Inc. (NYSE: 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers NRX Pharmaceuticals (NASDAQ:NRXP... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021
Upgrades For Callaway Golf Co (NYSE:ELY), Compass ... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Evercore ISI Group raised Lear Corporation (NYSE: 
Via Benzinga
46 Biggest Movers From Yesterday
Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares jumped 93.9% to close at $35.36 on Monday. The FDA removed the full clinical hold on Protagonist Therapeutics’... 
Via Benzinga
Exposures Product Safety
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
Toward the end of trading on Monday, the Dow traded down 0.37% to 34,617.17 while the Nasdaq fell 0.05% to 34,617.14. The S&P 500 also fell, dropping 0.26% to 4,379.88. Let's look at what has happened... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.37% to 34,617.17 while the NASDAQ fell 0.05% to 34,617.14. The S&P also fell, dropping 0.26% to 4,379.88. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares increased by 92.43% to $35.1 during Monday's regular session. Trading volume for this security as of 12:30 EST is... 
Via Benzinga
Where Protagonist Therapeutics Stands With Analysts
Within the last quarter, Protagonist Therapeutics (NASDAQ:PTGX) has observ... 
Via Benzinga
Mid-Day Market Update: Crude Oil Surges Over 2%; Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals
Midway through trading Monday, the Dow traded up 0.50% to 34,920.55 while the NASDAQ rose 0.50% to 34,920.55. The S&P also rose, gaining 0.44% to 4,410.73. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.